Literature DB >> 34318360

Is combination of immunosuppressive drugs the answer to reduce glucocorticoid burden in patients with lupus nephritis?

Kunal Chandwar1, Sapan Pandya2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34318360     DOI： 10.1007/s10067-021-05868-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


× No keyword cloud information.
  9 in total

1.  Effect of treatment on the evolution of renal abnormalities in lupus nephritis.

Authors:  J E Balow; H A Austin; L R Muenz; K M Joyce; T T Antonovych; J H Klippel; A D Steinberg; P H Plotz; J L Decker
Journal:  N Engl J Med       Date:  1984-08-23       Impact factor: 91.245

2.  Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis.

Authors:  Michael Walsh; Peter A Merkel; Chen-Au Peh; Wladimir M Szpirt; Xavier Puéchal; Shouichi Fujimoto; Carmel M Hawley; Nader Khalidi; Oliver Floßmann; Ron Wald; Louis P Girard; Adeera Levin; Gina Gregorini; Lorraine Harper; William F Clark; Christian Pagnoux; Ulrich Specks; Lucy Smyth; Vladimir Tesar; Toshiko Ito-Ihara; Janak Rashme de Zoysa; Wojciech Szczeklik; Luis Felipe Flores-Suárez; Simon Carette; Loïc Guillevin; Charles D Pusey; Alina L Casian; Biljana Brezina; Andrea Mazzetti; Carol A McAlear; Elizabeth Broadhurst; Donna Reidlinger; Samir Mehta; Natalie Ives; David R W Jayne
Journal:  N Engl J Med       Date:  2020-02-13       Impact factor: 91.245

3.  Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids.

Authors:  Marie B Condon; Damien Ashby; Ruth J Pepper; H Terence Cook; Jeremy B Levy; Megan Griffith; Tom D Cairns; Liz Lightstone
Journal:  Ann Rheum Dis       Date:  2013-06-05       Impact factor: 19.103

4.  Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis.

Authors:  M Zeher; A Doria; J Lan; G Aroca; D Jayne; I Boletis; F Hiepe; H Prestele; P Bernhardt; Z Amoura
Journal:  Lupus       Date:  2011-10-05       Impact factor: 2.911

5.  Avacopan for the Treatment of ANCA-Associated Vasculitis.

Authors:  David R W Jayne; Peter A Merkel; Thomas J Schall; Pirow Bekker
Journal:  N Engl J Med       Date:  2021-02-18       Impact factor: 91.245

6.  Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.

Authors:  Richard Furie; Brad H Rovin; Frédéric Houssiau; Ana Malvar; Y K Onno Teng; Gabriel Contreras; Zahir Amoura; Xueqing Yu; Chi-Chiu Mok; Mittermayer B Santiago; Amit Saxena; Yulia Green; Beulah Ji; Christi Kleoudis; Susan W Burriss; Carly Barnett; David A Roth
Journal:  N Engl J Med       Date:  2020-09-17       Impact factor: 91.245

7.  Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.

Authors:  Frédéric A Houssiau; Carlos Vasconcelos; David D'Cruz; Gian Domenico Sebastiani; Enrique de Ramon Garrido Ed; Maria Giovanna Danieli; Daniel Abramovicz; Daniel Blockmans; Alessandro Mathieu; Haner Direskeneli; Mauro Galeazzi; Ahmet Gül; Yair Levy; Peter Petera; Rajko Popovic; Radmila Petrovic; Renato Alberto Sinico; Roberto Cattaneo; Josep Font; Geneviève Depresseux; Jean-Pierre Cosyns; Ricard Cervera
Journal:  Arthritis Rheum       Date:  2002-08

8.  Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial.

Authors:  Shunsuke Furuta; Daiki Nakagomi; Yoshihisa Kobayashi; Masaki Hiraguri; Takao Sugiyama; Koichi Amano; Takeshi Umibe; Hajime Kono; Kazuhiro Kurasawa; Yasuhiko Kita; Ryutaro Matsumura; Yuko Kaneko; Keita Ninagawa; Keiju Hiromura; Shin-Ichiro Kagami; Yosuke Inaba; Hideki Hanaoka; Kei Ikeda; Hiroshi Nakajima
Journal:  JAMA       Date:  2021-06-01       Impact factor: 56.272

9.  Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.

Authors:  Brad H Rovin; Y K Onno Teng; Ellen M Ginzler; Cristina Arriens; Dawn J Caster; Juanita Romero-Diaz; Keisha Gibson; Joshua Kaplan; Laura Lisk; Sandra Navarra; Samir V Parikh; Simrat Randhawa; Neil Solomons; Robert B Huizinga
Journal:  Lancet       Date:  2021-05-07       Impact factor: 79.321
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.